Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Wasle, I; Gamerith, G; Kocher, F; Mondello, P; Jaeger, T; Walder, A; Auberger, J; Melchardt, T; Linkesch, W; Fiegl, M; Mian, M.
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.
Ann Hematol. 2015; 94(4):593-601
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Linkesch Werner
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
The anthracycline doxorubicin plays a major role in the treatment of lymphoproliferative disorders. However, its use is often limited due to cardiac toxicity, which seems to be much less in the liposomal non-pegylated formulation (Myocet®). The aim of this study was the evaluation of efficacy and toxicity of Myocet®-containing treatment regimens, with a focus on cardiotoxicity during treatment in lymphoma patients. A total of 326 consecutive patients, treated between March 2008 and December 2013 in 11 Austrian and 1 Italian cancer centers, were retrospectively assessed. Patients' baseline and treatment-related parameters were obtained by reviewing hospital records. Median age was 74 years (range 26-93). The most common histology was DLBCL (60 %), followed by FL (13 %) and MCL (8 %). At least one cardiovascular comorbidity was present in 72 % of patients. Most common grade 3/4 toxicities were hematologic, namely, leukopenia, neutropenia, thrombocytopenia, and febrile neutropenia in 44, 40, 17, and 16 %. Overall, 43 patients suffered a cardiac event (any grade) with most patients developing congestive heart failure. Parameters significantly associated with severe cardiac events (grades 3-5) were the presence of cardiovascular comorbidities, chronic obstructive pulmonary disease, and elevated baseline NT-proBNP. Treatment response after first line Myocet®-containing therapy was ≥58 % among all entities (range 58-86 %) and therefore comparable to those of conventional therapeutic regimens. Herein, we provide a detailed toxicity profile of Myocet®-containing chemotherapy regimens. Despite the high rate of patients with preexisting comorbidities, the number of adverse events was encouraging. However, these results need to be confirmed in a prospective randomized trial.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Antibiotics, Antineoplastic - therapeutic use
Doxorubicin - analogs & derivatives
Doxorubicin - therapeutic use
Drug-Related Side Effects and Adverse Reactions - epidemiology
Female -
Humans -
Lymphoma - drug therapy
Lymphoma - epidemiology
Male -
Middle Aged -
Polyethylene Glycols - therapeutic use
Retrospective Studies -
Treatment Outcome -

Find related publications in this database (Keywords)
Anthracycline
Cardiac toxicity
Lymphoma
Myocet
R-CHOP
© Meduni Graz Impressum